🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ASCO2025 was filled with groundbreaking science. Feeling inspired and grateful to be part of this community. These are just a few of the top breast cancer studies presented, and some of the remaining questions.

In women with node-positive breast cancer whose nodes became free of disease after neoadjuvant therapy, regional nodal irradiation did not reduce breast cancer recurrence or improve survival. Full results from a phase 3 trial: nej.md/4dM6LjD

💡☝🏽Broad panel-based NGS genomic testing🧬for non-metastatic #ColorectalCancer should be in the guidelines: We have ▪️PIK3CA consider testing statement➡️Aspirin💊 Don’t miss your ▪️MSS POL-E patient🟰immunotherapy💉 BRAF, HER2, MSI, & 🔜KRAS for adjuvant➕trials. OncoAlert

Brian Rini, MD Thank you for the likes!! Valame MD DNB Vania

Key facts for treatment selection in first-line therapy of ROS1 fusion-positive NSCLC👇 dailynews.ascopubs.org/do/selecting-f…

📗Management of HCC CA: A Cancer Journal for Clinicians ✅ A review from diagnosis to treatments 👉doi.org/10.3322/caac.7… OncoAlert #cancer #Oncology #MedX #liver

⚡️ Comprehensive review on perioperative management in urothelial carcinoma: - Immunotherapy & ADCs in neoadjuvant and adjuvant settings - Novel biomarkers (ctDNA, TIGIT/PD-1, DNA methylation) - Bladder-sparing approaches and quality of life considerations - Distinct

This tiny device can shrink dangerous blood clots. It’s called the ‘milli-spinner’ and its invention was partly an accident…

How to improve outcome in advanced ovarian epithelial cancer post 1st line chemotherapy and sx ? Add IO or parp inhibitors or both or none ? Money slide to summarize all 4 new trials in this space. Taken from #ASCO25 ASCO Kate Sears OncoAlert

For readers interested in bispecific antibodies in oncology, here's a comprehensive review nature.com/articles/s4157… rdcu.be/eqxm5

Now that Taletrectinib is approved by @usfda for metastatic NSCLC Check out the comparison of data for three ROS-1 inhibitors, entrectinib , repotrectinib and Taletrectinib. Useful for quick summary of data for all 3 . Rami Manochakian MD, FASCO Cancer Education OncoAlert Oncology Brothers Kate Sears

🫁 Summary of immunotherapies early stage NSCLC 1/3 ⭐️ Key clinical data as of June 2025 ※ #ASCO25 data included.

What patients are eligible for adjuvant CDK4/6i? We looked at this in ConcertAI: the approval of ribo doubled the pts eligible for adjuvant CDK4/6i (15%➡️30%) and provided an option for 10% of pts with N0 disease, those with the most aggressive cancers. esmoopen.com/article/S2059-…

Thank you to all colleagues who voted in the 2025 #ESMO election I'm honored to announce that I was elected as Director of Membership 😊 my aim is to extend ESMO - Eur. Oncology benefits to much more members across the globe!

Successful presentation stepwise process University of southern California

Key Myeloma therapy update for 2025 1) Newly diagnosed: Start treatment with quads, if possible. (Dara-VRd or Isa-VRd). 2) Auto Transplant: can be deferred for standard risk patients, especially if good response to induction. But collect and store stem cells for future use.

Dr. Sara Tolaney (Sara Tolaney) discusses findings from the phase III ASCENT-04/KEYNOTE-D19 study, which compared #SacituzumabGovitecan + #Pembrolizumab vs chemotherapy plus pembrolizumab in previously untreated patients with #PDL1–positive advanced #TripleNegativeBreastCancer

📢 #FDA approved another bladder-preserving treatment! The intravesical mitomycin gel offers a new option for patients with recurrent low-grade NMIBC. In the last 5 years, therapeutic alternatives have expanded meaningfully. A hopeful era for bladder preservation. 🌟 📊 See

⚡️ Molecular subtyping of urothelial carcinoma using just 4 common IHC markers (GATA3, KRT5, KRT14, KRT20). - Cost-effective, clinically relevant - Luminal subtype linked to better OS - Valuable for early stratification in limited-resource settings journals.lww.com/appliedimmunoh…

OF: Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial 📰Authors Neeraj Agarwal, MD, FASCO, Sumanta K. Pal, MD, FASCO, and colleagues thelancet.com/journals/lanon… ✏️Commentary from Deborah Mukherji, aurelius omlin thelancet.com/journals/lanon…